VLP Therapeutics

About VLP Therapeutics

This author has not yet filled in any details.
So far VLP Therapeutics has created 43 blog entries.

VLP Therapeutics to Present at International Conference on Vaccines R&D 2015

2015.11.02|

VLP Therapeutics, LLC. (“VLP”) announced that its Chief Executive Officer, Dr. Wataru Akahata, will present at the International Conference on Vaccines Research and Development 2015 on Tuesday, November 3, 2015, at 4:00 p.m. Eastern Time. The event will take place at the DoubleTree by Hilton Baltimore-BWI Airport in Linthicum, Maryland.

VLP Therapeutics to Initiate Collaboration with National Cancer Center in Japan

2015.06.04|

VLP Therapeutics, LLC. (“VLP”) announced that it has initiated a research collaboration with the National Cancer Center’s National Cancer Center Research Institute in Japan. The collaboration will help facilitate VLP’s research and development of cancer vaccine candidates.

VLP Therapeutics to Initiate Collaboration with Johns Hopkins University Bloomberg School of Public Health

2015.06.04|

VLP Therapeutics, LLC. (“VLP”) announced that it has initiated a research collaboration with John’s Hopkins University Bloomberg School of Public Health to research VLP’s malaria vaccine candidates.

VLP Therapeutics Enters Collaboration with Institute of Tropical Medicine, Nagasaki University

2015.04.01|

VLP Therapeutics, LLC. (“VLP”) announced that it has entered into a research collaboration with the Institute of Tropical Medicine at Nagasaki University in Japan. The collaboration will facilitate VLP’s research and development of dengue vaccine candidates.

VLP Therapeutics Enters Collaboration with Mitsubishi Heavy Industries

2015.03.17|

VLP Therapeutics, LLC. (“VLP”), a Gaithersburg-based biotechnology company focusing on the research and development of therapeutic and preventative vaccines and next generation antibody agents based upon a novel and proprietary vaccine technology, today announced that it has entered into a collaboration with Mitsubishi Heavy Industries to facilitate VLP’s on-going research and development of virus like particles.

VLP Therapeutics Wins the 2015 Life Sciences Impact Grant Award from the Montgomery County Department of Economic Development

2015.03.02|

VLP Therapeutics, LLC. (“VLP”), a Gaithersburg-based biotechnology company focusing on the research and development of therapeutic and preventative vaccines and next generation antibody agents based upon a novel and proprietary vaccine technology, today announced that it received a 2015 Life Sciences Impact Grant Award from the Montgomery County Department of Economic Development (MCDED).

VLP Therapeutics Appoints Dr. Ryuji Ueno as Chair and Chief Medical Officer

2014.03.25|

VLP Therapeutics, Inc. ("VLP"), a Rockville-based biotechnology company focusing on the research and development of next generation antibody agents and therapeutic as well as preventive vaccines based upon a novel and proprietary i-αVLP technology (which stands for "inserted alpha virus like particle"), today announced that Ryuji Ueno, M.D., Ph.D., Ph.D., Co-Founder and former Chair, Chief Executive Officer and Chief Scientific Officer of Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP) ("Sucampo") will join VLP as Chair and Chief Medical Officer, effective today.